HUAREN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.31 CNY | -0.60% |
|
-6.50% | -21.56% |
| Apr. 04 | Huaren Pharma's Unit Gets Nod for Medical Device | MT |
| Feb. 22 | Huaren Pharma's Unit Gets Nod to Add Specifications to Antibiotic Product | MT |
| Sales 2021 | 1.56B 216M | Sales 2022 | 1.62B 224M | Capitalization | 5.01B 692M |
|---|---|---|---|---|---|
| Net income 2021 | 130M 17.96M | Net income 2022 | 181M 25M | EV / Sales 2021 | 4.55 x |
| Net Debt 2021 | 1.42B 197M | Net Debt 2022 | 1.45B 200M | EV / Sales 2022 | 3.99 x |
| P/E ratio 2021 |
43.6
x | P/E ratio 2022 |
27.7
x | Employees | 2,264 |
| Yield 2021 |
0.38% | Yield 2022 |
0.5% | Free-Float | 36.65% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.60% | ||
| 1 week | -6.50% | ||
| Current month | -7.54% | ||
| 1 month | -10.05% | ||
| 3 months | -13.35% | ||
| 6 months | -18.67% | ||
| Current year | -21.56% |
1 week
3.15
3.57
1 month
3.153.75
Current year
2.864.35
1 year
2.864.60
3 years
2.866.03
5 years
2.867.43
10 years
2.8617.74
| Managers | Title | Age | Since |
|---|---|---|---|
Liang Hong
CEO | Chief Executive Officer | 53 | 22-12-28 |
Li Ping Han
DFI | Director of Finance/CFO | 39 | 20-10-25 |
Xiao Dong Yang
CHM | Chairman | 56 | 19-07-18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gen Fu Feng
BRD | Director/Board Member | 67 | 19-08-27 |
Tian Xi Zhang
BRD | Director/Board Member | 67 | 19-08-27 |
Li Qiang
CHM | Chairman | 63 | 19-08-05 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 3.31 | -0.60% | 7,835,464 |
| 24-04-18 | 3.33 | -1.19% | 11,313,460 |
| 24-04-17 | 3.37 | +6.65% | 17,591,140 |
| 24-04-16 | 3.16 | -7.33% | 21,841,680 |
| 24-04-15 | 3.41 | -3.67% | 16,023,520 |
End-of-day quote Shenzhen S.E., April 18, 2024
More quotes
Huaren Pharmaceutical CO.,LTD is a China-based company principally engaged in the research, development, manufacture and distribution of non polyvinyl chloride (PVC) soft bag large volume preparations. The Company provides basic infusion products, including sodium chloride infusions, dextrose infusions and compound sodium chloride infusions, among others; infusion products for treatment, including metronidazole and sodium chloride infusions, ciprofloxacin lactate and sodium chloride infusions and others, as well as nutritious infusion products, among others. The Company distributes its products in domestic market, with Northeast China as its main market.
Sector
Pharmaceuticals
Calendar
2024-04-24
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -21.56% | 540M | |
| +20.91% | 43.82B | |
| +16.96% | 21.73B | |
| +9.05% | 13.95B | |
| +7.98% | 13.03B | |
| +33.80% | 11.13B | |
| -11.05% | 6.8B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +6.64% | 5.05B |
- Stock Market
- Equities
- 300110 Stock
